TRDA's Business Model
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.entradatx.com |
| CEO (Chief Executive Officer) | Dipal Doshi |
| Number of Employees | |
| IPO date | October 29, 2021 |
TRDA Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 6 Tide Street |
| City | Boston |
| State | MA |
| Phone | 857 520 9158 |
| Zip Code | 02210 |
| Other Identifiers | |
| CIK | 0001689375 |
| ISIN | US29384C1080 |
| CUSIP | 29384C108 |
| Open | 10.82 |
| Previous Close | 10.8 |
| Volume | 182.5 Thou. |
| Average Volume | 219.7 Thou. |
| Day’s Range | 10.69 – 11.16 |
| 52 Week Range | 4.93-13.82 |
| MA (50) | 10.769 |
| MA (200) | 7.8603 |
| Market Cap | 415.8 Mil. |
| Shares Out. | 38.22 Mil. |
| Earnings Date | Mar 18, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
